Case report and review: IVIg and efgartigimod in Guillain-Barré with Graves disease and thyroid cancer
Doctors treat a rare relapse of Guillain-Barré syndrome with new immune therapies
This case report and literature review describes a 33-year-old man with Guillain-Barré syndrome, Graves disease, and papillary thyroid carci…
A 33-year-old man with Guillain-Barré syndrome found relief after doctors treated his underlying thyroid cancer and used new immune therapie…
Meta-analysis of efgartigimod for myasthenia gravis reports efficacy and safety outcomes
New analysis shows intravenous efgartigimod helps many myasthenia gravis patients feel better and reduces symptoms quickly
This meta-analysis of 1594 patients with myasthenia gravis synthesized outcomes for intravenous efgartigimod. The authors report high rates …
A large review of data found that a new medicine called efgartigimod helps most patients with myasthenia gravis feel better. About eight out…
Efgartigimod improved MG-ADL and QMG scores in 81 Chinese patients with generalized myasthenia gravis
Many Myasthenia Gravis Patients Need Just One Treatment Cycle
This single-center, retrospective analysis evaluated efgartigimod in 81 Chinese patients with generalized myasthenia gravis.
Most patients with myasthenia gravis controlled symptoms after a single treatment cycle, with fewer infusions possible for some.
Sequential efgartigimod and rituximab induced improvement in three patients with refractory autoimmune encephalitis
Sequential efgartigimod and rituximab showed improvement in three patients with autoimmune encephalitis
This case series describes three patients with refractory autoimmune encephalitis treated with sequential efgartigimod and rituximab.
Three patients with difficult autoimmune encephalitis improved after sequential treatment, suggesting a potential new option for those who d…
Efgartigimod shows homogeneous efficacy across sexes in AChR-Ab+ generalized myasthenia gravis
New Hope for All Myasthenia Gravis Patients
This post hoc, sex-specific subgroup analysis of the ADAPT Phase 3 RCT evaluated efgartigimod in 86 females and 43 males with AChR-Ab+ gener…
A new treatment for myasthenia gravis works equally well for women and men, offering the same relief from severe muscle weakness regardless …
Efgartigimod showed higher independent walking at week 4 and running at week 12 versus IVIG in GBS patients unable to walk
A Newer Drug Outperformed the Standard Treatment for a Paralyzing Nerve Disease
This single-center retrospective study evaluated efgartigimod versus intravenous immunoglobulin (IVIG) in 34 Guillain-Barré syndrome patient…
A newer drug helped 100% of paralyzed Guillain-Barré patients walk again in four weeks, outperforming the standard treatment in a recent stu…
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis
New Drugs Double Your Chance of Getting Better
A meta-analysis of 739 adults in RCTs and 588 in OLEs with acetylcholine receptor antibody-positive generalized myasthenia gravis found that…
New drugs for generalized myasthenia gravis double the odds of meaningful improvement while reducing the need for rescue therapy and severe …